HIGHLIGHTS
- who: Immunosuppression and collaborators from the SKKU Advanced Institute of Nanotechnology (SAINT), Department of, School of Chemical, Sungkyunkwan University, Suwon, Republic of Korea have published the article: Nanoengineered Drug Delivery in Cancer Immunotherapy for Overcoming Immunosuppressive Tumor Microenvironment, in the Journal: (JOURNAL)
- what: The current trial is being conducted to investigate the effectiveness of combination therapy with checkpoint inhibitors (nivolumab and ipilimumab) .
SUMMARY
Inhibitory molecules such as programmed death-ligand 1 (PD-L1) deactivate T_cells. Major histocompatibility complex (MHC) II and T_cell receptor (TCR) interaction, accompanied by cluster of differentiation (CD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.